Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
蛋白多糖对肿瘤血管生成和内皮细胞自噬的调节
基本信息
- 批准号:10634656
- 负责人:
- 金额:$ 37.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAffinityAllograftingAngiogenesis InhibitorsAngiogenic FactorAngiostatic ProteinsAutophagocytosisBindingBiologicalBiologyBreast Cancer cell lineBreast CarcinomaC-terminalCancer BiologyCellsCellular StressChemicalsCommunicationComplexCore ProteinCuesDevelopmentDiseaseEIF-2alphaEatingEndothelial CellsEndotheliumEnzymesExonsFemaleFibroblast Growth Factor ReceptorsFundingGene TargetingGeneticGenetic TranscriptionGrantGrowthHAS2 geneHeparan Sulfate ProteoglycanHyaluronanImmunologicsIn VitroIntegrinsKDR geneKnowledgeLaboratoriesLigationLinkMalignant NeoplasmsMediatingMethodologyModalityModelingMolecularMusMutateNamesNeoplasm MetastasisNutrientOxygenPTPN6 geneParentsParkinPathway interactionsPhosphoric Monoester HydrolasesPhosphorylationPhosphorylation SitePhosphotransferasesProtein Tyrosine PhosphataseProteinsProteoglycanRecombinantsRegulationResearchRoleSecond Primary CancersSensitivity and SpecificitySignal TransductionSpecificityStromal CellsTamoxifenTechnologyTestingTimeTransgenic MiceTranslatingTumor AngiogenesisVEGFA geneVascular EndotheliumVascularizationWorkZebrafishadhesion receptoraggressive breast cancerangiogenesisantagonistattenuationcancer cellcell behaviorcellular engineeringclinically relevantcombatconfocal imagingexperimental studygenetic signaturein vivoinducible Creinhibitorinnovationinterdisciplinary approachmTOR InhibitormTOR inhibitionmalignant breast neoplasmmortalitymouse modelmutantnano-stringneoplastic cellneovascularizationnovelnovel therapeuticsnutrient deprivationoverexpressionparacrineperlecanpredict clinical outcomeprogramspromoterreceptorsensortranscriptometranscriptomicstumortumor microenvironmenttumor progressiontumorigenesistumorigenicultra high resolution
项目摘要
Chief among female mortality is the development, progression, and metastasis of aggressive breast cancer. The
bidirectional communication between the neoplastic cells and the tumor microenvironment, which supplies
oxygen and nutrients, is essential for promoting unchecked tumorigenic development, aberrant
neovascularization, and widespread metastasis. Thus, a better understanding of embedded cues and soluble
messages exchanged between these two compartments will prove invaluable for furthering our knowledge of
the pathobiology of cancer and for reliably predicting clinical outcomes.
Our central hypothesis is that endorepellin, a proteolytic fragment of perlecan, a multi-domain heparan sulfate
proteoglycan, exploits a dual-receptor antagonism to preclude endothelial cells from participating in tumor
angiogenesis. This working hypothesis is based on an impactful and promising body of work all generated under
the auspices of this grant. We discovered that: [a] Endorepellin simultaneously ligates, with high affinity,
VEGFR2 and the 21 integrin thereby constituting the molecular basis of “dual receptor antagonism”.
Engagement of both receptors underscores the exquisite sensitivity and specificity of endorepellin in targeting
the endothelia. [b] Endorepellin triggers co-internalization of VEGFR2 and 21 integrin with concurrent
activation of the SHP-1 tyrosine phosphatase and attenuation of VEGFA signaling. [c] Endorepellin induces
endothelial cell autophagy in a Peg3-dependent manner by modulating Beclin 1, LC3, and p62 expression,
processing, and cellular localization. [d] Endorepellin evokes protracted activation of the energy-sensor kinase
AMPK, irrespective of energy levels. Indeed, this regulation is considered non-canonical as AMPK
phosphorylation occurred under nutrient-enriched conditions. [e] Downstream of AMPK, endorepellin evokes
autophagic flux in endothelial cells that mechanistically parallels the mTOR inhibitor, Torin 1. These striking
findings demonstrate that protracted and sustained autophagy is a novel mechanism by which endorepellin
promotes angiostasis, independent of nutrient deprivation. Based on these discoveries, we plan to:
[1] Elucidate the mechanism of endorepellin-evoked endothelial cell stress, autophagy and mitophagy.
[2] Unravel the mechanism by which endorepellin induces autophagic suppression of HAS2.
[3] Generate novel mouse models of tumorigenesis to explain the pro-autophagic and anti-angiogenic programs
activated by endorepellin.
These concerted research aims will enable us to translate our findings, procured with highly innovative mouse
models of stromal autophagy, into clinically relevant paradigms. The discovery of endorepellin-induced
endothelial cell autophagy downstream of dual receptor antagonism will lead to new therapeutic advances that
actively induce autophagy within the tumor microenvironment to combat this devastating disease.
女性凡人的主要是发展
肿瘤细胞与肿瘤微环境之间的双向通信,该环境提供
氧气和营养,对于促进未检查的肿瘤发育至关重要,异常
新生血管和宽度转移。
这两个隔间之间交换的消息将证明我们对
癌症病理生物学以及可靠地预测临床结果。
我们的中心假设是内核蛋白,一种多域硫酸乙酰肝素的蛋白水解片段
蛋白聚糖,利用双受体拮抗作用,使内皮细胞无法参与肿瘤
血管生成。
这项赠款的主持人。
VEGFR2和211整联蛋白所构成的“双重受体拮抗作用”的分子基础。
两种受体的参与强调了靶向靶向的精致敏感性和特异性
内皮。
SHP-1酪氨酸磷酸盐的激活和VEGFA信号的注意。
内皮细胞细胞以PEG3依赖性方式自噬,通过调节Beclin 1,LC3和P62表达,
处理和细胞定位。
Ampk,无论能量水平是否,该法规都被认为是非典型的
磷酸化发生在养分 - 富裕条件下。
在机械上与MTOR抑制剂合同的内皮细胞中的自噬通量,Torin 1。
调查结果表明,长期和持续的自噬是一种新型机制
根据这些发现,促进了与营养剥夺无关的血管疾病。
[1]阐明了内螺旋蛋白诱发的触地式触发细胞应激,自噬和线粒体的机制。
[2]揭示了内核诱导诱导自噬抑制HAS2的机制。
[3]生成新型的肿瘤发生小鼠模型,以解释亲噬型和Andi -Ngiogenic程序
由内核蛋白激活。
这些协调的研究目的将使我们能够翻译我们的发现,并以高度创新的鼠标购买
基质自噬的模型,临床相关的范例。
内皮细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞细胞和细胞t t
积极诱导肿瘤微环境中的Itophapy,以打击这种毁灭性疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RENATO V. IOZZO其他文献
RENATO V. IOZZO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RENATO V. IOZZO', 18)}}的其他基金
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
蛋白多糖对肿瘤血管生成和内皮细胞自噬的调节
- 批准号:
10818834 - 财政年份:2020
- 资助金额:
$ 37.79万 - 项目类别:
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
蛋白多糖对肿瘤血管生成和内皮细胞自噬的调节
- 批准号:
10186719 - 财政年份:2020
- 资助金额:
$ 37.79万 - 项目类别:
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
蛋白多糖对肿瘤血管生成和内皮细胞自噬的调节
- 批准号:
10439783 - 财政年份:2020
- 资助金额:
$ 37.79万 - 项目类别:
Altered Proteoglycan Gene Expression and Cancer
蛋白多糖基因表达改变与癌症
- 批准号:
7909761 - 财政年份:2009
- 资助金额:
$ 37.79万 - 项目类别:
相似国自然基金
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
面向免疫疗法标志物识别的基于多特征融合的肽与MHC亲和力预测研究
- 批准号:62302277
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向多场景应用的药物-靶标结合亲和力预测研究
- 批准号:62371403
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
- 批准号:
10434937 - 财政年份:2021
- 资助金额:
$ 37.79万 - 项目类别:
Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab
用 Clazakizumab 治疗肺移植受者的炎症和同种免疫
- 批准号:
10282620 - 财政年份:2021
- 资助金额:
$ 37.79万 - 项目类别:
A Rapid Point of Care Test for APOL1 Renal Risk Alleles
APOL1 肾脏风险等位基因的快速护理检测
- 批准号:
10257344 - 财政年份:2021
- 资助金额:
$ 37.79万 - 项目类别:
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
- 批准号:
10302501 - 财政年份:2021
- 资助金额:
$ 37.79万 - 项目类别:
Mechanisms of alloantibody production following renal transplantation
肾移植后同种抗体产生的机制
- 批准号:
10357956 - 财政年份:2021
- 资助金额:
$ 37.79万 - 项目类别: